Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine.

Fiche publication

Date publication

mai 2018

Journal

Breast cancer (Tokyo, Japan)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PIVOT Xavier

Tous les auteurs :
Pivot X, Im SA, Guo M, Marmé F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29302858

Résumé

This post hoc subgroup analysis of a large phase 3 study compared the efficacy and safety of eribulin versus capecitabine in patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who received second-line treatment. In the phase 3 study, women with advanced/metastatic breast cancer and ≤ 3 prior chemotherapies were randomized 1:1 to eribulin mesilate 1.4 mg/m intravenously on days 1 and 8, or twice-daily oral capecitabine 1.25 g/m on days 1-14 (21-day cycles). This analysis included 392 patients. Median overall survival was longer in patients receiving eribulin compared with capecitabine (16.1 vs 13.5 months, respectively; HR 0.77, P = 0.026). Median progression-free survival and response rates were similar between arms. Both treatments had manageable safety profiles.